Home » Tenders » Europe » Germany » Open House Contracts for Several Active Ingredients / Active Ingredient Combinations Tender

Open House Contracts for Several Active Ingredients / Active Ingredient Combinations Tender

Download Documents

AOK NORDWEST - THE HEALTH INSURANCE FUND has floated a tender for Open House Contracts for Several Active Ingredients / Active Ingredient Combinations. The project location is Germany and the tender is closing on 01 Sep 2022. The tender notice number is 487840-2020, while the TOT Ref Number is 46640814. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Procurement Summary

Country : Germany

Summary : Open House Contracts for Several Active Ingredients / Active Ingredient Combinations

Deadline : 01 Sep 2022

Other Information

Notice Type : Tender

TOT Ref.No.: 46640814

Document Ref. No. : 487840-2020

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : AOK NORDWEST - THE HEALTH INSURANCE FUND
Address: Copenhagener Str. 1
Town: Dortmund
NUTS code: DEA - NORTH RHINE-WESTPHALIA
Postal Code: 44269
Germany
Email :openhouse@nw.aok.de
URL :www.aok.de

Tender Details

Document Type: Contract notice

Title: Open house contracts for several active ingredients / active ingredient combinations

Reference Number: 2020-10-12-NW-KRA-Open House

Contract Type: Supplies

Description: The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active ingredients / active ingredient combinations in the context of a so-called open house procedure:
- Bimatoprost (S01EE03);

- paliperidone (N05AX13);

- Budensonide (A07EA06) only hard capsules with modified release of active ingredients;

- Aprepitant (A04AD12) excl. Packs with 2 components and N1 packs with WS strength 80 mg;

- Cinacalcet (H05BX01);

Iron (II) sulfate (B03AA07);

- hydroxychloroquine (P01BA02);

- lenogastrim (L03AA10);

- nadroparin (B01AB06);

- emtricitabine / tenofovir disoproxil / rilpivirine (J05AR08);

- nitrofurantoin (J01XE01);

- clonazepam (N03AE01).

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies will be able to conclude a discount agreement in accordance with Section 130a (8) SG ... subject to standard contractual conditions and a standardized access procedure.